RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Nuove strategie terapeutiche per la orbitopatia basedowiana
• 2 - Valutazione degli effetti, genomici e non, di un analogo selettivo della T3 (DITPA) sulla funzione cardiaca, sul profilo metabolico e sulla vasodilatazione endotelio-dipendente nell’animale da esperimento ed in pazienti con scompenso cardiaco, in presenza o meno di Sindrome da bassa-T3.
• 3 - Studio clinico randomizzato di fase III per valutare l’efficacia e la tollerabilità di un trattamento integrato (dietetico, farmaco-nutrizionale e farmacologico) in pazienti neoplastici con anoressia/cachessia e stress ossidativo correlati al cancro.
• 4 - Ezio-patogenesi della fibrosi retroperitoneale idiopatica
• 5 - Valutazione del possibile impiego di cellule staminali di origine midollare mobilizzate nel sangue periferico, per la rigenerazione di tessuti non-emopoietici
• 6 - UTILIZZO DI ERITROCITI AUTOLOGHI COME BIOREATTORI PER IL RILASCIO DI FARMACI NELLA PREVENZIONE DELLA RESTENOSI DOPO IMPIANTO DI STENT CORONARICO
• 7 - Meccanismi patogenetici che condizionano l'espressione fenotipica dell'obesità e la risposta alla terapia
• 8 - Malattia di Parkinson e stimolazione dopaminergica: alterazioni cardiovascolari, comportamentali e della vigilanza
• 9 - Meccanismi dell'angina pectoris cronica nei pazienti con coronarografie normali
• 10 - Studio prospettico di pazienti in età pediatrica affetti da sindrome di Tourette, Tic e/o disturbo ossessivo-compulsivo: relazione con le infezioni da streptococco Beta-emolitico gruppo A.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA CLINICA
  • MALATTIE DELL'APPARATO CARDIOVASCOLARE
  • ENDOCRINOLOGIA
  • MALATTIE DEL SANGUE
  • DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • DIAGNOSIS; SURGERY; IDENTIFICATION (analysing biological material G01N, e.g. G01N33/48; obtaining records using waves other than optical waves, in general G03B42/00)
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Lombardia

Bibliografia

1. Epstein SE et al. Sudden cardiac death without warning. Possible mechanisms and implications for screening asymptomatic populations. N Engl J Med 1989;321:320-4.
2. Di Chiara A et al. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003;24:1616-29.
3. Grines CL et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-9.
4. Halkin A et al. Prognostic implications of creatinine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2006;47:951-61.
5. Ndrepepa G et al. N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis. Am J Cardiol 2006;97:1151-6.
6. Biagini E et al. Comparison between contrast echocardiography and magnetic resonance imaging to predict improvement of myocardial function after primary coronary intervention. Am J Cardiol 2006;97:361-6.
7. Gerber BL et al. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patients after acute myocardial infarction. Circulation 2002;106:1083-9.
8. Sandstede JJ et al. Analysis of first-pass and delayed contrast-enhancement patterns of dysfunctional myocardium on MR imaging: use in the prediction of myocardial viability. Am J Roentgenol 2000;174:1737–40.
9. James SK et al. End-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A GUSTO-IV substudy. Circulation 2003;108:275-81.
10. Conti E et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation 2004;110:2260-5.
11. Andreotti F et al. Heart-kidney interactions in ischemic syndromes. Circulation 2004;109:31-2.
12. Smith KJ et al. The cardiovascular effects of erythropoietin. Cardiovascular Res 2003;59:538-48.
13. Bogoyevitch MA. An update on the cardiac effects of erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 2004;63:208-16.
14. Coleman T et al. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Critical Care 2004;8:337-41.
15. van der Meer et al. Erythropoietin and cardiovascular diseases. Eur Heart J 2004;25:285-91.
16. Maiese K et al. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5.
17. Shraples EJ et al. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol 2006; Feb 14.
18. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care 2004;8:337-41.
19. Cai Z et al. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004;109:2050-3.
20. van de Meer P et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 2004;6:853-9.
21. Heeschen C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6.
22. Messina E et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004;95:911-21.
23. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med 2003;228:1-14.
24. Digicalylioglu M et al. Acute neuroprotective synergy of erythropietin and insulin-like growth factor-1. PNAS 2004;26:9855-60.
25. Conti E et al. Unraveling Reaven’s syndrome X: serum insulin-like growth factor-1 and cardiovascular disease. Circulation 2003;107:e190-92.
26.Tramontano AF et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003;308:990-4.
27. Parsa CJ et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
28. Calvillo L et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS 2003;100:4802-6.
29. Moon C et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. PNAS 2003;100:11612-7.
30. Cai Z et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79-85.
31. Strauer BE et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002;106:1913-8.
32. Schachinger V et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004;44:1690-9.
33. Ehrenreich H et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
34. Mancini DM et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-9.
35. Silverberg DS et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775-80. 36. Silverberg DS et al. The effect of correction of diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
37. Bohlius et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
38. Iseki K et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron 1996;72:30-6.
39. Wakeen M et al. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998;32:488-93.
40. Besarab A et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
41. Miyashita K et al. Blood pressure response to erythropoietin injection in hemodyalisis and predialysis patients. Hypertens Res 2004;27:79-84.
42. Linde T et al. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. Scand J Urol Nephrol 1996;30:115-20.
43. Lipsic E et al. A single bolus of long-acting erythropoietin analogue darbepoetin in patients with an acute myocardial infarction: a randomized feasibility and safety study. 2005 Am Heart Association Scientific Sessions.
44. Bennett CL et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005;106:3343-7.
45. Shin DH et al. Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318000 units a day in acute myocardial infarction: report of two cases. Basic Clin Pharmacol Toxicol 2006;98:222-4.

Parole Chiave

INFARTO MIOCARDICO ACUTO, ERITROPOIETINA, ESTENSIONE AREA INFARTUALE, RIMODELLAMENTO CARDIACO, RIPERFUSIONE MIOCARDICA, INDICI NECROSI MIOCARDICA, APOPTOSI, FUNZIONE VENTRICOLARE SINISTRA